Austrianova Singapore Overview
- Year Founded
-
2007
- Status
-
Private
- Employees
-
12
- Latest Deal Type
-
Later Stage VC
- Investors
-
7
Austrianova Singapore General Information
Description
Developer of a cell encapsulation technology designed to protect, isolate, store and transport human and animal cells. The company's offerings include the utilization of a proprietary living-cell encapsulation technology for mammalian and bacterial cells which is designed to protect the encapsulated cells from rejection by the immune system by allowing the cells to be transported, stored, and implanted at specific sites in patients, enabling doctors and healthcare organizations to deliver strong cells and medicine in patients with weak immune systems.
Contact Information
Website
www.austrianova.comCorporate Office
- 2 International Business Park
- Level 09 - Unit Number 04, The Strategy IBP (Tower 1)
- Singapore, 609930
- Singapore
Corporate Office
- 2 International Business Park
- Level 09 - Unit Number 04, The Strategy IBP (Tower 1)
- Singapore, 609930
- Singapore
Austrianova Singapore Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC | 01-Jan-2025 | Completed | Generating Revenue | |||
| 4. Later Stage VC | 01-Mar-2023 | Completed | Generating Revenue | |||
| 3. Later Stage VC | 07-Jul-2021 | Completed | Generating Revenue | |||
| 2. Later Stage VC (Series B) | 05-Jun-2007 | $47.2M | $88.6M | Completed | Generating Revenue | |
| 1. Later Stage VC | $41.4M | $41.4M | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Austrianova Singapore Comparisons
Industry
Financing
Details
Austrianova Singapore Competitors (18)
One of Austrianova Singapore’s 18 competitors is Feldan Therapeutics, a Venture Capital-Backed company based in Quebec, Canada.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Feldan Therapeutics | Venture Capital-Backed | Quebec, Canada | ||||
| LifeTein, LLC | Corporation | Hillsborough, NJ | ||||
| Jackson ImmunoResearch Laboratories | Corporation | West Grove, PA | ||||
| TILT Biotherapeutics | Venture Capital-Backed | Helsinki, Finland | ||||
| Numaferm | Venture Capital-Backed | Dusseldorf, Germany |
Austrianova Singapore Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Austrianova Singapore Patents
Austrianova Singapore Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2020900269-A0 | Probiotic formulation and delivery | Inactive | 31-Jan-2020 | ||
| AU-2021213029-A1 | Probiotic formulation and delivery | Active | 31-Jan-2020 | ||
| AU-2021213029-B2 | Probiotic formulation and delivery | Active | 31-Jan-2020 | ||
| CA-3169611-A1 | Probiotic formulation and delivery | Pending | 31-Jan-2020 | ||
| EP-4096426-A1 | Probiotic formulation and delivery | Pending | 31-Jan-2020 | A61P1/00 |
Austrianova Singapore Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Austrianova Singapore Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Checkmate Capital | Venture Capital | Minority | ||
| 144 Ventures | Venture Capital | Minority | ||
| UntroD | Venture Capital | Minority | ||
| AT Treuhand | Corporation | Minority | ||
| Omni Technology Invest | Venture Capital | Minority |
Austrianova Singapore Investments (2)
Austrianova Singapore’s most recent deal was a Joint Venture with Klothonova. The deal was made on 18-Sep-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Klothonova | 18-Sep-2025 | Joint Venture | Biotechnology | ||
| Insulinova | Joint Venture | Drug Discovery |
Austrianova Singapore FAQs
-
When was Austrianova Singapore founded?
Austrianova Singapore was founded in 2007.
-
Where is Austrianova Singapore headquartered?
Austrianova Singapore is headquartered in Singapore, Singapore.
-
What is the size of Austrianova Singapore?
Austrianova Singapore has 12 total employees.
-
What industry is Austrianova Singapore in?
Austrianova Singapore’s primary industry is Drug Delivery.
-
Is Austrianova Singapore a private or public company?
Austrianova Singapore is a Private company.
-
What is Austrianova Singapore’s current revenue?
The current revenue for Austrianova Singapore is .
-
How much funding has Austrianova Singapore raised over time?
Austrianova Singapore has raised $88.6M.
-
Who are Austrianova Singapore’s investors?
Checkmate Capital, 144 Ventures, UntroD, AT Treuhand, and Omni Technology Invest are 5 of 7 investors who have invested in Austrianova Singapore.
-
Who are Austrianova Singapore’s competitors?
Feldan Therapeutics, LifeTein, LLC, Jackson ImmunoResearch Laboratories, TILT Biotherapeutics, and Numaferm are some of the 18 competitors of Austrianova Singapore.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
